Sponsor

United Therapeutics

Clinical research sponsor

How to interpret these research links

Connected source records

The exact organization name United Therapeutics appears in 84 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials84
Recruiting shown1
Roles2
SourceClinicalTrials.gov
Advertisement

Clinical trials

60 shown
DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)NCT06388421 · lead sponsor · 2025-01-23
RECRUITING
Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier DetectionNCT05776225 · lead sponsor · 2023-08-11
COMPLETED
Evaluate Real-World Use of Next Generation Infusion Pumps to Administer RemodulinNCT05060315 · lead sponsor · 2023-07-05
TERMINATED
A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial HypertensionNCT05203510 · lead sponsor · 2022-10-20
ACTIVE_NOT_RECRUITING
Study of Ralinepag on Exercise Capacity by Cardiopulmonary Exercise Testing (CPET) in WHO Group 1 PH SubjectsNCT04084678 · lead sponsor · 2021-01-20
TERMINATED
A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label ExtensionNCT03683186 · lead sponsor · 2019-09-23
ENROLLING_BY_INVITATION
Open-label, Clinical Study to Evaluate the Safety and Tolerability of TreT in Subjects With PAH Currently Using TyvasoNCT03950739 · lead sponsor · 2019-09-17
COMPLETED
Patient Global Impression Questions for Activity-Induced Symptoms in Participants With PAHNCT03888365 · lead sponsor · 2019-04-01
COMPLETED
EXPEDITE: A Study of Remodulin Induction Followed by Orenitram Optimization to Treat Pulmonary Arterial HypertensionNCT03497689 · lead sponsor · 2019-01-31
COMPLETED
A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH PatientsNCT03626688 · lead sponsor · 2019-01-24
COMPLETED
Inhaled Treprostinil in Participants With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)NCT03794583 · lead sponsor · 2018-12-21
TERMINATED
A Phase 3 Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Participants With Pulmonary Hypertension (PH) Due to Chronic Obstructive Pulmonary Disease (COPD)NCT03496623 · lead sponsor · 2018-05-08
TERMINATED
Open-label Extension of Oral Treprostinil in Subjects With PH Associated With HFpEFNCT03043651 · lead sponsor · 2018-01-30
TERMINATED
Study to Compare Triple Therapy (Oral Treprostinil, Ambrisentan, and Tadalafil) With Dual Therapy (Ambrisentan, Tadalafil, and Placebo) in Subjects With Pulmonary Arterial HypertensionNCT02999906 · lead sponsor · 2017-10-01
WITHDRAWN
Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection FractionNCT03037580 · lead sponsor · 2017-08-15
TERMINATED
ADAPT - A Patient Registry of the Real-world Use of Orenitram®NCT03045029 · lead sponsor · 2017-07-18
ACTIVE_NOT_RECRUITING
Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung CancerNCT03098030 · lead sponsor · 2017-06-01
COMPLETED
An Open Label Extension Study to Evaluate the Safety of Continued Therapy of Subcutanous Remodulin® in Pulmonary Arterial HypertensionNCT02882126 · lead sponsor · 2017-06-01
WITHDRAWN
Study to Evaluate Efficacy and Safety of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Sickle Cell Disease (SCD)NCT03055234 · lead sponsor · 2017-06-01
WITHDRAWN
Safety of Transition From Selexipag to Remodulin® Then Oral Treprostinil in Symptomatic Adult PAHNCT03016468 · lead sponsor · 2017-05-01
WITHDRAWN
Safety and Tolerability of Inhaled Treprostinil in Adult PH Due to COPDNCT03012646 · lead sponsor · 2017-04-01
WITHDRAWN
Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFENCT02630316 · lead sponsor · 2017-02-03
COMPLETED
Safety, Tolerability, Pharmacokinetics and Efficacy of Two Different Rates of Subcutanous Remodulin® Dose Titration in Pulmonary Arterial HypertensionNCT02893995 · lead sponsor · 2017-02-01
WITHDRAWN
An Open Label Extension Study to Evaluate Inhaled Treprostinil in Adult PH With ILD Including CPFENCT02633293 · lead sponsor · 2016-09-15
TERMINATED
Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary FibrosisNCT02603068 · lead sponsor · 2016-02-01
WITHDRAWN
Remodulin as Add-on Therapy for the Treatment of Persistent Pulmonary Hypertension of the NewbornNCT02261883 · lead sponsor · 2015-07-29
TERMINATED
Long-term Safety and Efficacy of Ralinepag in Pulmonary Arterial HypertensionNCT02279745 · lead sponsor · 2015-07-08
COMPLETED
Safety, Tolerability, and Pharmacokinetics of Oral Treprostinil in Pediatric PAH Patients Aged 7 to 17 YearsNCT02276872 · lead sponsor · 2014-12-18
COMPLETED
Safety and Efficacy of APD811 in Pulmonary Arterial HypertensionNCT02279160 · lead sponsor · 2014-12-01
COMPLETED
An Open-Label, Long-Term Study of Oral Treprostinil in Subjects With Pulmonary Arterial HypertensionNCT01560637 · lead sponsor · 2013-09-11
COMPLETED
A Pharmacokinetic Substudy of the TDE-PH-304 ProtocolNCT01934582 · lead sponsor · 2013-08-01
COMPLETED
Safety Study of PLX-PAD Cells to Treat Pulmonary Arterial Hypertension (PAH)NCT01795950 · lead sponsor · 2013-04-01
TERMINATED
Tyvaso Dosing and Titration Evaluation: TyTRATE RegistryNCT01799473 · lead sponsor · 2013-01-01
COMPLETED
Phase III Clinical Worsening Study of UT-15C in Subjects With PAH Receiving Background Oral MonotherapyNCT01560624 · lead sponsor · 2012-06-26
COMPLETED
Safety and Efficacy of Inhaled Treprostinil in Patients With PAHNCT01557647 · lead sponsor · 2012-06-01
WITHDRAWN
Inhaled Treprostinil for PAH: Open-label ExtensionNCT01557660 · lead sponsor · 2012-06-01
WITHDRAWN
Remodulin® to Oral Treprostinil TransitionNCT01588405 · lead sponsor · 2012-04-01
COMPLETED
Safety and Tolerability of Rapid Dose Titration of Subcutaneous Remodulin® Therapy in PAH Subjects (RAPID)NCT02847260 · lead sponsor · 2012-04-01
COMPLETED
Addition of UT-15C SR to Pulmonary Arterial Hypertension Patients Currently Receiving Tyvaso®NCT01477333 · lead sponsor · 2011-10-01
COMPLETED
A Study to Assess the Safety and Efficacy of Treprostinil to Facilitate Liver Transplantation in Patients With Portopulmonary HypertensionNCT01028651 · lead sponsor · 2011-01-01
COMPLETED
Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH TherapiesNCT01266265 · lead sponsor · 2010-12-01
COMPLETED
A Bioavailability Study Comparing Treprostinil Diethanolamine Oral Tablets and Oral Solution in Healthy VolunteersNCT01172496 · lead sponsor · 2010-08-01
COMPLETED
Comparative Bioavailability of Treprostinil Diethanolamine Manufactured by Two Independent FacilitiesNCT01165476 · lead sponsor · 2010-07-01
COMPLETED
Pharmacokinetic Linearity and Comparative Bioavailability of Treprostinil DiethanolamineNCT01153386 · lead sponsor · 2010-07-01
COMPLETED
The Effect of Renal Impairment on the Pharmacokinetics of Oral TreprostinilNCT01131845 · lead sponsor · 2010-05-01
COMPLETED
A Dose Response Study of UT-15C SR in Patients With Exercise-Induced Pulmonary HypertensionNCT01104870 · lead sponsor · 2010-04-01
COMPLETED
Effect of Esomeprazole on the Pharmacokinetics of Oral TreprostinilNCT00963027 · lead sponsor · 2009-09-01
COMPLETED
Effect of Food on the Pharmacokinetics of Oral TreprostinilNCT00963001 · lead sponsor · 2009-09-01
COMPLETED
Efficacy and Safety of Oral UT-15C Tablets to Treat Pulmonary Arterial HypertensionNCT00887978 · lead sponsor · 2009-06-01
COMPLETED
FREEDOM DR: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor or as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)NCT00760916 · lead sponsor · 2008-12-01
WITHDRAWN
Safety Evaluation of Inhaled Treprostinil Administration Following Transition From Inhaled Ventavis in Pulmonary Arterial Hypertension (PAH) SubjectsNCT00741819 · lead sponsor · 2008-09-01
COMPLETED
Rapid Switch From Flolan to Remodulin in the Outpatient ClinicNCT00643604 · lead sponsor · 2008-03-01
TERMINATED
Transitioning To IV Remodulin From Ventavis in Patients With PAH: Safety, Efficacy and Treatment SatisfactionNCT00458042 · lead sponsor · 2007-03-01
TERMINATED
Safety, Efficacy, and Treatment Satisfaction Switching From Flolan to Remodulin Using the Crono Five Ambulatory Pump in Patients With PAHNCT00439946 · lead sponsor · 2007-02-01
TERMINATED
An Open-Label Extension Trial of UT-15C Sustained-release (SR) in Subjects With Pulmonary Arterial HypertensionNCT01027949 · lead sponsor · 2007-01-16
COMPLETED
FREEDOM-C: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor for the Treatment of Pulmonary Arterial Hypertension (PAH)NCT00325442 · lead sponsor · 2006-10-01
COMPLETED
FREEDOM - M: Oral Treprostinil as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)NCT00325403 · lead sponsor · 2006-10-01
COMPLETED
Safety, Efficacy and Treatment Satisfaction in Patients With PAH Rapidly Switched From Epoprostenol to RemodulinNCT00373360 · lead sponsor · 2006-09-01
COMPLETED
TRUST-2: Safety and Efficacy of Intravenous Remodulin® in Patients in India With Pulmonary Arterial Hypertension (PAH)NCT03055221 · lead sponsor · 2005-06-10
COMPLETED
Clinical Investigation Into Inhaled Treprostinil Sodium in Patients With Severe Pulmonary Arterial Hypertension (PAH)NCT00147199 · lead sponsor · 2005-06-01
COMPLETED

Sponsor roles

lead sponsor63
collaborator21
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.